Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homarylamine SCHEMBL29412731 | 1.00 | TAAR1 (0.61) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2471267 | 0.90 | TAAR1 (0.57) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL9608844 | 0.89 | LMNA (0.52) | TAAR1KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL27650175 | 0.88 | HDAC1 (0.56) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL30928242 | 0.88 | HDAC1 (0.56) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL30496700 | 0.85 | POLB (0.66) | TAAR1KDM4EALDH1A1LMNAPKM | |
| SCHEMBL9736670 | 0.83 | POLB (0.59) | TAAR1KDM4EALDH1A1LMNAPKM | |
| SCHEMBL108087 | 0.82 | TAAR1 (0.77) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL14205398 | 0.82 | TAAR1 (0.61) | TAAR1SLC6A4KDM4EALDH1A1LMNA | |
| SCHEMBL29261883 | 0.82 | TAAR1 (0.61) | TAAR1CYP2D6KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-12043605-B2 | Deuterated empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-117956991-A | N, N-dimethyltryptamine and related hallucinogens and uses thereof | 人类生物科学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023081899-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| WO-2023283373-A1 | 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED PSYCHEDLICS AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-5120759-A | TETRAHYDRONAPHTHALENE DERIVATIVES FOR IMPROVING SHORT-TERM MEMORY | HOFFMANN-LA ROCHE INC. (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0065229-B1 | BENZAZEPINES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS | Dr. Karl Thomae GmbH (DE) | 1985-08-07 | — | — | EP | disclosed |
| EP-0065229-A1 | Benzazepines, process for their preparation and their application as pharmaceutical preparations | Dr. Karl Thomae GmbH (DE) | 1982-11-24 | — | — | EP | disclosed |
| US-4134980-A | Phenylalkylamino-alkyl derivatives of quinazolinone and phthalazinone | BOEHRINGER INGELHEIM GMBH (DE) | 1979-01-16 | — | — | US | disclosed |
| US-4087541-A | REDUCING HEART RATE | BOEHRINGER INGELHEIM GMBH (DT) | 1978-05-02 | — | — | US | disclosed |
| US-4058607-A | DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES | AIRWICK INDUSTRIES, INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4038407-A | HEART RATE SLOWING DRUGS | BOEHRINGER INGELHEIM GMBH (DT) | 1977-07-26 | — | — | US | disclosed |
| US-3962415-A | Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer | AIRWICK INDUSTRIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043605-B2 | Deuterated empathogens | SLC18A2, SLC6A3, GAP43 | TAAR1 59/4885SLC6A2 5/4885SLC6A4 10/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | TAAR1 32/4885SLC6A2 322/4885SLC6A4 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.